Fujifilm India Pvt. Ltd. is pleased to announce that FUJIFILM Corporation has introduced X-ray solutions augmented with qXR*1, Qure.ai’s computed aided radiology software application designed with deep-learning Artificial Intelligence (AI) technology. According to Qure.ai, the AI will analyze X-ray images to detect abnormal findings within seconds. Fujifilm’s portable X-ray FDR Xair system are equipped with a new image processing box called Expansion Unit EX-Mobile*2 enabling to connect with qXR software. It will assist clinicians and technicians by flagging abnormal findings at the point-of-care.
FDR Xair system and EX-Mobile
qXR Critical Care
Qure’s peer-reviewed and proven chest X-ray interpretation technology, qXR can detect suspected abnormalities indicative of COVID-19, tuberculosis, lung cancer, misplaced catheters and multiple other radiological findings allowing for further review and confirmatory testing. The technology has been extensively trained on a global dataset and can be used for both adult as well as pediatric images.
Another significant advancement is that the combination of EX-Mobile with Fujifilm’s portable X-ray FDR Xair system will bring the benefit of Qure’s AI technology not only to hospitals, but also regions which are geographically distant from the cities and emergency critical care. Furthermore, it will respond to the rapidly increasing global demand for support for effective lung procedures at medical sites, especially during the disease outbreaks.
“Fujifilm and Qure’s technology will deliver a support tool to assist the care providers for accurate diagnosis faster. With the help of Technology and special examination we can diagnose the disease while it is asymptomatic, with no signs or symptoms. The earlier detection of disease may lead to more cures or longer survival. Our partnership with Qure will support the expansion of Tuberculosis(TB) screening in India, and also other developing countries where there is limited access to such health service. We believe there's tremendous potential in this partnership” said Koji Wada, General Manager, Fujifilm India Medical Division.
“We are delighted to partner with Fujifilm to improve quality of care by accelerating patient triage, diagnostics and treatment. Qure.ai’s CE- certified and WHO endorsed technology will elevate patient care and reduce radiologists’ workload across healthcare institutions.” said Prashant Warier, CEO and Co-Founder, Qure.ai.
Fujifilm customers will be able to select one of the clinical packages available with qXR including:
- qXR-COVID-19 which helps to monitor change of lung density.
- qXR-Lung Nodule that enables early detection of metastatic lung cancer by automated pulmonary nodule detection.
- qXR-TB helps reduce the waiting time for confirmatory tests for diseases like Tuberculosis.
- qXR-Critical Care can detect misplaced catheters and tubes which are commonly used in critical care settings for monitoring body functions and administering medications.
Fujifilm and Qure aims provide high quality care in the increasingly dynamic and complex healthcare environment through future-proof AI technology.
※1 Available in select CE Mark countries. Not available in all regions.
※2 Expansion Unit EX-Mobile is option product of Fujifilm’s FDR D-EVO II DR cassette.
Qure.ai is a breakthrough Artificial Intelligence (AI) solution provider that is disrupting the radiology ‘status quo’ by enhancing imaging accuracy and improving health outcomes with the assistance of machine-supported tools. Qure.ai taps deep learning technology to provide automated interpretation of radiology exams like X-rays, CTs and MRI scans for time and resource-strapped medical imaging professionals—enabling faster diagnosis and speed to treatment. Qure.ai is helping to make healthcare more accessible and affordable to patients worldwide.
About Fujifilm India Pvt. Ltd.
Fujifilm India Private Limited was established as a wholly owned subsidiary of Fujifilm Holdings Corporation, Tokyo in India on 4th December 2007. The Japanese leader in a broad spectrum of medical imaging technologies, operates in India through its head office and is supported branch offices and by huge network of Indian dealers, with over 50,000 installations across the country.
Fujifilm India is continuously working towards early detection of disease and generating awareness among general public by conducting awareness programs, for promoting TB and cancer screening.
About FUJIFILM Holdings Corporation,
Brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $22.1 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.